Access and affordability in diabetes

All people diagnosed with diabetes should receive treatment 

The medicines exist to treat diabetes successfully and affordably, even in the poorest settings. But today there are tens of millions of people living with diabetes who cannot get the life-saving insulin that they need – because it is too costly alongside other necessities in life, or in some parts of the world isn’t on the shelf when it is needed.

As the world’s biggest producer of medicines for diabetes, we stand on the frontline of the challenge of affordability and availability. It’s our ambition that everyone who needs our essential medicines can access them, at prices that they can afford. 

 

5 million people with diabetes treated with our human insulun at a maximum price of 4 USD per 10ML vial

In 2018, 5 million people with diabetes were treated with our human insulin at a maximum of 4 USD per 10ml vial

Our Changing Diabetes in Children programme has provided treatment to 19,000+ chilfren with type 1 diabetes

Our Changing Diabetes in Children® programme has provided treatment to 19,000+ children with type 1 diabetes

We donated 85 million Danish Kroner to the World Diabetes Foundation

In 2018, we donated 85 million Danish Kroner to the World Diabetes Foundation
 


Pricing of our medicines

When we determine how to price our medicines, we consider a number of country specific factors: the value that the medicine brings to patients, how the medicine compares with alternative treatments for the same disease, the local healthcare system and other socio-economic factors.

Insulin is a special case. For people with type 1 diabetes and for some people with type 2 diabetes, it is an essential, life-saving medicine for which there is no alternative. It’s our ambition that everyone who needs insulin has access to it at prices they can afford.

 

Our access to insulin commitment

Our Access to Insulin Commitment guarantees that we will provide low-priced human insulin for people living with diabetes in low- and middle-income countries.

Today, our commitment covers 78 countries, home to 124 million people with diabetes, as well as selected humanitarian organisations operating in crisis areas. 

Read about our Access to Insulin Commitment


Medicines affordability in the US

We recognise that some people with diabetes in the United States are increasingly finding it hard to pay for their healthcare, including our diabetes medicines.

Ensuring access and affordability is a responsibility we share with all involved in healthcare and we are going to do our part.

Our efforts to make medicine affordable for US patients



How we work to improve access to diabetes care

The diabetes challenge hits underserved communities the hardest, especially those in low- and middle-income countries. When barriers to medicine and basic healthcare put people living with diabetes at risk of developing complications such as heart disease, blindness, kidney damage and amputations.

Our efforts in low- and middle-income countries focus on people who are the most vulnerable and we have put in place affordability and access programmes in over two-thirds of the countries where we operate.
 

 

Sujatha has type 2 diabetes, India

Our programmes & partnerships to improve global diabetes care

We are working through a growing range of partnerships to expand our efforts and embed solutions into our day-to-day business.

Through a combination of our programmes and partnerships, we are helping people access the care they need, no matter where they live.

Our programmes & partnerships

 

Treating people living with diabetes in the developing world

In 2002, we established the World Diabetes Foundation to invest hundreds of millions of dollars in the prevention and treatment of diabetes in low- and middle-income countries.

The Foundation’s network of public and private partners have helped shape the system of support for people with diabetes in countries around the world.

The World Diabetes Foundation




Access and affordability in haemophilia
 


Novo Nordisk Haemophilia Foundation
 

The Novo Nordisk Haemophilia Foundation (NNHF) is a grant-making, non-profit organisation that strives to improve access to care for people with haemophilia and allied bleeding disorders in developing and emerging countries.

Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people.1 75% of people with haemophilia live in the developing world, where most do not have a diagnosis or access to adequate care.

Learn more about the Novo Nordisk Haemophilia Foundation